Compare Fox Corp Class B (FOX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs TG Therapeutics Inc — how do they compare? Fox Corp Class B trades at $55.42 (market cap $25.36B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: Fox Corp Class B is far larger — about 3.1× TG Therapeutics Inc's market cap, and Fox Corp Class B pays a 1.02% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and TG Therapeutics Inc for 16 Days on average.
| FOX | TGTX | |
|---|---|---|
Market Cap | $25.36B | $8.16B |
Volume | 886,620 | 1,735,121 |
Sector | Media | Health |
52-Week High | $67.76 | $59.06 |
52-Week Low | $44.39 | $26.94 |
Typical Hold Time | 75 Days | 16 Days |
Enterprise Value | $28.72B | $8.37B |
Dividend Yield | 1.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX stock trades at $55.89, down 0.16% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.79 surpassing the $1.44 estimate. Revenue grew to $16.30 billion in 2025, and net income margin improved to 13.88%. Analysts maintain a consensus price target of $84.75, implying significant upside, with 42% recommending Buy.
The outlook is positive given earnings momentum and reasonable valuation multiples, but risks include projected net cash flow turning negative in 2026 and competitive pressures in media. Investor sentiment is supported by bullish analyst targets, though attention is needed on debt levels and future profitability trends.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
